Creative Biolabs Expands One-Stop Antibody CDMO Services from Discovery to cGMP Manufacturing
By bringing discovery-stage material generation and downstream biologics development into one coordinated workflow, the company aims to help biotechnology and pharmaceutical teams reduce technical handoffs, maintain data continuity, and advance antibody candidates more efficiently.
Antibody developers frequently rely on different service providers for gene synthesis, expression, purification, characterization, process optimization, and manufacturing. While this model can provide access to specialized technologies, fragmented outsourcing may introduce inconsistent methods, multiple technology transfers, variable documentation, and delays between discovery and development.
Creative Biolabs' one-stop CDMO solutions are structured to reduce these operational gaps. The platform covers cell line and expression-vector development, process development, analytical development, non-GMP and GMP manufacturing, quality control, aseptic fill/finish activities, and regulatory support. According to the company, flexible production scales from 2 L to 2,000 L are available for supported antibody modalities, alongside CMC documentation intended to facilitate later-stage development planning.
Connecting Antibody Discovery with Scalable Production
A major challenge in antibody discovery is converting a large number of sequence hits into purified, testable proteins quickly enough to support meaningful candidate selection. Slow or inconsistent material generation can become a bottleneck for functional screening, developability assessment, and lead optimization.
To address this need, Creative Biolabs provides high-throughput antibody production services that connect antibody sequence input with gene synthesis, vector construction, transfection, mammalian-cell expression, purification, and quality control. The platform is designed to generate hundreds of purified recombinant antibodies and may deliver selected projects in as little as two weeks, depending on project scope.
The workflow can support candidates originating from phage display, single B-cell screening, or AI-assisted antibody discovery. Phage-derived fragments can be reformatted into full-length immunoglobulins, while naturally paired heavy- and light-chain sequences from single B cells can be expressed for functional comparison. This allows discovery teams to evaluate candidates in application-relevant formats rather than relying only on sequence predictions or preliminary binding data.
"Successful antibody development depends on more than finding a molecule that binds its target," said a scientific representative from Creative Biolabs. "Researchers also need reproducible expression, sufficient material quality, functional activity, and a development path that can support scale-up. Integrating these requirements earlier can improve candidate-selection decisions."
Recombinant Antibodies for Research and Development Programs
The company's Hi-Affi™ recombinant antibody portfolio complements its production and CDMO services by providing recombinant antibodies generated through controlled expression systems. Available categories include human, humanized, chimeric, single-domain, rabbit monoclonal, mouse, and other antibody types.
Creative Biolabs reports purity levels above 98% for relevant products, with selected antibodies demonstrating affinity reaching the sub-nanomolar range. Bulk quantities from 1 mg to 10 g are also available, helping laboratories access consistent materials for assay development, screening, validation, and other research applications.
Because recombinant production uses defined antibody sequences, it can improve lot-to-lot reproducibility and facilitate subsequent engineering. Researchers can modify antibody format, Fc function, affinity, specificity, or other molecular properties while maintaining sequence traceability throughout the program.
August Webinar Explores Next-Generation Antibody Discovery
Creative Biolabs will also host the webinar "Novel Platforms for Preclinical Antibody Discovery" from 11:00 a.m. to 12:00 p.m. EDT on August 11, 2026. The session will feature Ivelin Georgiev, PhD, Professor at Vanderbilt University, discussing integrated wet-lab and AI-based platforms intended to improve the efficiency, scalability, and outcomes of monoclonal antibody discovery.
The August antibody discovery webinar will examine how computational and experimental workflows may reduce cost, complexity, and turnaround time while identifying antibody phenotypes that are difficult to obtain through conventional approaches.
About Creative Biolabs
Creative Biolabs is a biotechnology service provider offering integrated solutions for antibody discovery, engineering, production, characterization, process development, and biologics manufacturing. Its capabilities support academic, biotechnology, and pharmaceutical organizations working across discovery-stage research, preclinical development, and scalable production.
* For research use only. Not intended for clinical use.